Lilly Plumbs Data's Depths To Differentiate CDK4/6 Inhibitor Verzenio
Lilly highlighted five prognostic factors at SABCS that may be linked to high Verzenio response. As the third CDK4/6 inhibitor on the US market, the company needs to differentiate its breast cancer drug from Pfizer's Ibrance and Novartis's Kisqali.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Lilly's top-line Phase III JUNIPER data for abemaciclib in KRAS-mutated advanced non-small cell lung cancer may have disappointed, but the big pharma has vowed to continue evaluating the agent in this and in other cancers, and in combination therapies.
Lilly reported positive top-line results for abemaciclib in the Phase III MONARCH 2 trial and revealed a regulatory strategy that has it rapidly racing after competing CDK4/6 inhibitors already approved for certain breast cancer patients.